Immunology and Biotherapies
38.6K views | +4 today
Follow
 
Scooped by Gilbert C FAURE
onto Immunology and Biotherapies
July 22, 2:03 PM
Scoop.it!

Inhibition of IL-11 signalling extends mammalian healthspan and lifespan

Inhibition of IL-11 signalling extends mammalian healthspan and lifespan | Immunology and Biotherapies | Scoop.it
For healthspan and lifespan, ERK, AMPK and mTORC1 represent critical pathways and inflammation is a centrally important hallmark1–7. Here we examined whether IL-11, a pro-inflammatory cytokine of the IL-6 family, has a negative effect on age-associated disease and lifespan. As mice age, IL-11 is upregulated across cell types and tissues to regulate an ERK–AMPK–mTORC1 axis to modulate cellular, tissue- and organismal-level ageing pathologies. Deletion of Il11 or Il11ra1 protects against metabolic decline, multi-morbidity and frailty in old age. Administration of anti-IL-11 to 75-week-old mice for 25 weeks improves metabolism and muscle function, and reduces ageing biomarkers and frailty across sexes. In lifespan studies, genetic deletion of Il11 extended the lives of mice of both sexes, by 24.9% on average. Treatment with anti-IL-11 from 75 weeks of age until death extends the median lifespan of male mice by 22.5% and of female mice by 25%. Together, these results demonstrate a role for the pro-inflammatory factor IL-11 in mammalian healthspan and lifespan. We suggest that anti-IL-11 therapy, which is currently in early-stage clinical trials for fibrotic lung disease, may provide a translational opportunity to determine the effects of IL-11 inhibition on ageing pathologies in older people. IL-11 is identified as a key regulator of ERK–AMPK–mTORC1 signalling, metabolism, inflammation and age-related disease and lifespan in mouse and human.
No comment yet.
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
December 16, 2013 2:45 AM
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular.

Gilbert C FAURE's insight:

We use Scoop.it as preferred curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...                                                            Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further information on Immune monitoring of Immune therapies, 

http://www.scoop.it/t/immune-monitoring-1     by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

Thanks to K Maggon for joining us. @Krishan Maggon

 

No comment yet.
Scooped by Gilbert C FAURE
October 31, 5:03 AM
Scoop.it!

La Chine publie la première norme internationale pour les données sur les cellules souches — Chine Informations

La Chine publie la première norme internationale pour les données sur les cellules souches — Chine Informations | Immunology and Biotherapies | Scoop.it
La première norme internationale au monde pour les données sur les cellules souches, ISO8472-1, a été officiellement publiée, a annoncé mercredi l'Institut de...
No comment yet.
Scooped by Gilbert C FAURE
October 11, 4:48 AM
Scoop.it!

Un podcast de Besançon sur les Car-T cells

Un podcast de Besançon sur les Car-T cells | Immunology and Biotherapies | Scoop.it
sur votre plateforme audio préférée...
No comment yet.
Scooped by Gilbert C FAURE
September 27, 8:49 AM
Scoop.it!

Vaccines and Related Biological Products Advisory Committee September 20, 2024 Meeting Announcement - 09/20/2024 | FDA

Vaccines and Related Biological Products Advisory Committee September 20, 2024 Meeting Announcement - 09/20/2024 | FDA | Immunology and Biotherapies | Scoop.it
This is the main page for the CBER Vaccines and Related Biological Products Advisory Committee (VRBPAC) September 20, 2024 Meeting announcement and meeting materials.
No comment yet.
Scooped by Gilbert C FAURE
September 26, 1:48 PM
Scoop.it!

https://rupress.org/jem/article/221/11/e20240806/276977/Targeting-TNF-TNFR-superfamilies-in-immune?utm_content=308469623&utm_medium=social&utm_source=twitter&hss_channel=tw-75302402

No comment yet.
Scooped by Gilbert C FAURE
September 2, 7:40 AM
Scoop.it!

Intranasal vaccine shows broad SARS-CoV-2 variant protection

Intranasal vaccine shows broad SARS-CoV-2 variant protection | Immunology and Biotherapies | Scoop.it
Study demonstrates that a single-dose intranasal live-attenuated vaccine, CDO-7N-1, provides broad protection against SARS-CoV-2 and its variants by inducing potent immune responses, including neutralizing antibodies and T-cell activity, in animal models.
No comment yet.
Scooped by Gilbert C FAURE
August 14, 8:03 AM
Scoop.it!

https://www.nejm.org/doi/full/10.1056/NEJMe2401020

No comment yet.
Scooped by Gilbert C FAURE
August 13, 4:08 AM
Scoop.it!

Débora Gräf on LinkedIn: #rwd #rwe #eu #ema #medicinesregulation #vaccines

Débora Gräf on LinkedIn: #rwd #rwe #eu #ema #medicinesregulation #vaccines | Immunology and Biotherapies | Scoop.it
Really happy to share that my first PhD paper is out 😊 💉

"The life cycle of vaccines evaluated by the European Medicines Agency" is a review of vaccines…
No comment yet.
Scooped by Gilbert C FAURE
July 23, 10:23 AM
Scoop.it!

JAK Inhibitors Reduce Macular Degeneration | RheumNow

JAK Inhibitors Reduce Macular Degeneration | RheumNow | Immunology and Biotherapies | Scoop.it
Insurance claims data showed that patients with autoimmune disorders who took Janus kinase (JAK) inhibitors had lower rates of age-related macular degeneration (AMD), hinting that the drugs might treat the common eye disease.
No comment yet.
Scooped by Gilbert C FAURE
July 21, 6:31 AM
Scoop.it!

Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?

Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet? | Immunology and Biotherapies | Scoop.it
Despite significant advances in biologic and small molecule treatments and the emergence of combination therapies to treat inflammatory bowel diseases (IBD) a large unmet need remains to control intestinal inflammation.
No comment yet.
Scooped by Gilbert C FAURE
July 16, 1:56 PM
Scoop.it!

The present and future of bispecific antibodies for cancer therapy | Nature Reviews Drug Discovery

The present and future of bispecific antibodies for cancer therapy | Nature Reviews Drug Discovery | Immunology and Biotherapies | Scoop.it
Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic applications that cannot be achieved using conventional IgG-based antibodies. Consequently, development of these molecules has garnered substantial interest in the past decade and, as of the end of 2023, 14 bsAbs have been approved: 11 for the treatment of cancer and 3 for non-oncology indications. bsAbs are available in different formats, address different targets and mediate anticancer function via different molecular mechanisms. Here, we provide an overview of recent developments in the field of bsAbs for cancer therapy. We focus on bsAbs that are approved or in clinical development, including bsAb-mediated dual modulators of signalling pathways, tumour-targeted receptor agonists, bsAb–drug conjugates, bispecific T cell, natural killer cell and innate immune cell engagers, and bispecific checkpoint inhibitors and co-stimulators. Finally, we provide an outlook into next-generation bsAbs in earlier stages of development, including trispecifics, bsAb prodrugs, bsAbs that induce degradation of tumour targets and bsAbs acting as cytokine mimetics. Bispecific antibodies (bsAbs) can mediate therapeutic effects beyond those of natural monospecific antibodies. This Review provides an overview of recent developments in the field of bsAbs for cancer therapy and an outlook into next-generation bsAbs in earlier stages of development.
No comment yet.
Scooped by Gilbert C FAURE
July 16, 4:37 AM
Scoop.it!

Promised Cures, Tainted Cells: How Cord Blood Banks Mislead Parents –

Promised Cures, Tainted Cells: How Cord Blood Banks Mislead Parents – | Immunology and Biotherapies | Scoop.it
Millions of pregnant women get the pitch through their OB-GYN: Put a bit of your newborn’s umbilical cord on ice,...
No comment yet.
Scooped by Gilbert C FAURE
June 4, 3:48 AM
Scoop.it!

Stéphane Paul on LinkedIn: Notre nouvelle revue sur le monitoring des biothérapies

Stéphane Paul on LinkedIn: Notre nouvelle revue sur le monitoring des biothérapies | Immunology and Biotherapies | Scoop.it
Notre nouvelle revue sur le monitoring des biothérapies
No comment yet.
Scooped by Gilbert C FAURE
November 5, 7:20 AM
Scoop.it!

CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review | Oncology | JAMA | JAMA Network

CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review | Oncology | JAMA | JAMA Network | Immunology and Biotherapies | Scoop.it
This review summarizes evidence regarding cellular immunotherapies for cancer.
No comment yet.
Scooped by Gilbert C FAURE
October 17, 7:14 AM
Scoop.it!

https://www.cell.com/cell/fulltext/S0092-8674(24)00781-5

No comment yet.
Scooped by Gilbert C FAURE
October 1, 10:31 AM
Scoop.it!

Systemic dysregulation and molecular insights into poor influenza vaccine response in the aging population

No comment yet.
Scooped by Gilbert C FAURE
September 27, 8:48 AM
Scoop.it!

JCI Insight - An intranasally administered adenovirus-vectored SARS-CoV-2 vaccine induces robust mucosal secretory IgA

JCI Insight - An intranasally administered adenovirus-vectored SARS-CoV-2 vaccine induces robust mucosal secretory IgA | Immunology and Biotherapies | Scoop.it
This study demonstrated good safety, tolerability, and immunogenicity of Ad5-S-Omicron (NB2155), a replication-incompetent human Ad5 carrying Omicron BA.1 spike, as a monovalent intranasal booster in people who previously received injected inactivated whole-virus vaccines. Most AEs related to this nasal vaccine were mild, with comparable AEs and rates as other intranasal vaccines, such as FluMist, a live-attenuated influenza virus (LAIV), and an influenza virus–vectored COVID-19 vaccine (23, 24). Interestingly, solicited AEs, including oropharyngeal discomfort and nasal congestion, appeared to be much less noticeable after the second dose. Our preliminary observation also suggested that a 2-dose regimen may confer effective protection against Omicron infection even in a high–viral load environment. For participants who reported no infections, we monitored the elevation of nasal nucleocapsid-specific sIgA from day 0 to day 118 after the first dose to identify if there were any possible asymptomatic infections. We found that only 4 out of 29 of those 2-dose participants (13.8%) had a noticeable elevation of nasal nucleocapsid-specific sIgA between day 14 and day 90 after the second dose, suggesting that they might have an asymptomatic infection, though we could not exclude if extremely close contact with the discharged material from infected people may also induce such elevation. One of the most remarkable findings was that the second dose dramatically induced nasal spike-specific sIgA against 10 SARS-CoV-2 strains ranging from wild-type, Beta, Delta, to all Omicron subvariants tested. Strikingly, the elevation magnitude of 2 doses (51.5-fold increase) was much higher than that of 1 dose (4.5-fold increase), suggesting the importance of the second dose of intranasal booster. Our result differed from clinical studies of 2 nasal vaccines using simian-derived adenoviral vectors, AZD1222 (ChAdOx1 nCoV-19) and BBV154. Using the same MSD method for detecting spike-specific IgA, AZD1222 only generated a >3-fold elevation of nasal IgA against wild-type spike in 18.2% of participants but no IgA against other spikes (25). BBV154 induced a 1.56-fold elevation of salivary IgA against wild-type spike on day 42 over day 0 as measured by ELISA but had no reported effect on nasal IgA (26). Of note, ChAdOx1 is SAdY25 isolated from fecal samples, which may not have the best tissue tropism on nasopharyngeal mucosa (27). BBV154 vaccine used simian Ad36, which was isolated from a nonrespiratory tissue, and the vaccine was delivered by nasal drop rather than intranasal spray (28). We employed human Ad5, initially isolated from the human tonsil, which may have the ideal tissue tropism for the nasopharyngeal tract (15). Despite the vaccination site being in the nasal passage and our primary goal being to stimulate mucosal immunity, especially spike-specific sIgA against BA.1, we could also detect a modest induction of serum-neutralizing antibodies. The 88.9%–100% conversion rate of serum neutralizing antibodies against wild-type, BA.1, and BA.5 was higher than other intranasal vaccines reported thus far. We found that the elevation and titer of serum neutralizing titers were biased toward wild-type after the first dose of intranasal vaccination, likely due to the immune imprinting effect from the previously injected wild-type vaccines. However, the second dose of the Omicron vaccine could overcome the imprinting effect on serum antibodies. In contrast, nasal mucosal spike-specific sIgA elevation was comparable between wild-type and BA.1, without apparent influence from previously injected wild-type vaccines. These results suggested that the nasal mucosal and systemic immune responses are somewhat compartmentalized. Therefore, assessing nasal mucosal sIgA is a more relevant immunological correlate than serum antibodies for nasal vaccines. Preexisting immunity against adenovirus is one concern in repeated usage of adenoviruses, especially adenoviruses with high seroprevalence as vaccine vectors. Previous clinical studies using an Ad5-vectored influenza vaccine suggested that intranasal vaccinations were effective in the presence of preexisting anti-Ad5 immunity (29). In our study, the nasal spike-specific sIgA showed a greater elevation (average 10-fold) between the first and second doses. Thus, the second dose remained effective even in the presence of presumably the anti-Ad5 immunity induced by the first dose. We speculate that the presence of limited anti-Ad5 immunity in the nasal passage was insufficient to completely block the influx of a large bolus of Ad5 vaccine. We may thus call each intranasal influx of a large bolus of Ad5 vaccine a “breakthrough vaccination.” In addition to adenoviruses for COVID-19 vaccines, other viral vectors, such as an LAIV carrying RBD, have been used for intranasal vaccination. In a clinical study (23), 12%–18% positive conversion of RBD-specific IgA in nasopharyngeal swab samples and 10%–22% seroconversion of RBD-specific IgG was observed, but no results on serum neutralization were reported. This vaccine showed 28.2% effectiveness against Omicron infection in people aged 18–59 but has not been tested in children. FluMist, an intranasal seasonal influenza vaccine based on cold-adapted LAIV, is more efficacious than intramuscularly injected vaccines for protecting children (30). LAIV induced a weak serum antibody response but more elevation of mucosal IgA and conferred comparable protection to the intramuscularly injected vaccine in adults (31). So far, we have tested this Ad5-vectored intranasal vaccine only in adults. Future studies should address the immunogenicity and protection effectiveness of different intranasal vaccines in children, adults, and people who are aged. We propose that using different viruses as a vaccine vector; viruses of different serotypes or species of origin; and different antigen selection (RBD or spike), antigen gene design and optimization, expression cassette, formulation, and method of administration (such as intranasal spraying or dropping) may contribute to different immunological outcome and protection efficacy. The hallmark of our intranasal vaccine was the induction of broad-spectrum spike-specific sIgA in the nasal passage. Although this study did not evaluate the neutralization titers in NMLFs because of the constraint of sample collection, earlier studies by our team and other investigators have shown that nasal IgA in NMLFs possesses neutralizing activities against SARS-CoV-2 (17, 32, 33). It has been established that the risk of breakthrough infection was lower in convalescents with higher levels of nasal or salivary spike-specific sIgA (6, 7). In another study, we purified paired nasal sIgA, serum IgG, and IgA from NMLFs and serum samples and compared their neutralizing activities against both pre-Omicron strains and Omicron subvariants (34). Nasal sIgA can be over 100-fold more potent than serum IgG and IgA in neutralizing Omicron subvariants, including XBB and JN.1. The primary objective of this study was to evaluate the safety and immunogenicity of intranasal vaccination, which was not designed to assess protection efficacy. The zero-COVID policy was lifted when this study began. Many participants were infected before the vaccination could induce sufficient immune barrier to counter infection, and these infected participants had to drop out of the study. We observed that 43 out of 75 participants (57.3%) were infected days 15–28 after the first dose, December 14–30, 2022, suggesting that 1 dose with 4.5-fold induction of nasal spike-specific sIgA was not sufficient to block infection in an extremely high–viral load environment. Interestingly, 29 participants who received the second dose December 28–30, 2022, whose nasal spike-specific sIgA elevated 51.5-fold, reported no infection in the following 3 months, demonstrating that the second dose is critical for preventing at least symptomatic infection. In the same period, the accumulated infection rate in the population increased from less than 1% on December 7, 2022, to over 85% on January 18, 2023, according to a public announcement by the Guangzhou Municipal Health Commission (19). A report based on detecting SARS-CoV-2 ORF8 seroconversion also showed that the infection attack ratio was over 80.7% for samples collected January 5–14, 2023 (18). The limitation of this study in assessing protection effectiveness was the lack of a placebo group to monitor the infection rate with the exact timing as the intranasally vaccinated group, which may have an impact given the dynamic epidemic curve between the first and second doses administered. The exclusion of infected participants also lessened the study population. Nevertheless, we believe that the 2-dose regimen is more effective than 1 dose in preventing infection: 1) there was a time overlap between people who received the first dose and the second dose (December 28–30, 2022); 2) except for 2 participants who were infected on days 1 and 3 after the second dose, no more infections were reported as the nasal spike-specific sIgA elevated to 51-fold over the baseline; 3) according to a China CDC report (35), the infection rate based on PCR test started to increase on December 8, 2022; peaked on December 25, 2022, at 29.2%; and then decreased gradually but still was 5.5% on January 23, 2023. When participants received the second dose December 28–30, 2022, the infection rate in the population was at a high level. In particular, these participants were health care workers who worked in a respiratory disease hospital, where many patients with COVID-19 came in for medical care. Therefore, they were constantly exposed to a high–viral load environment. A randomized, placebo-controlled clinical study should be conducted in the future to obtain a more conclusive result. As the level of nasal spike-specific sIgA decreases over time, the chance of infection may increase. We found that nasal spike-specific sIgA decreased to 18.2-fold over baseline 3 months after the second dose but was still much higher than 4.5-fold after the first dose, keeping these people uninfected. Concurrent with a report that nasal sIgA wanes to the baseline level in 9 months after natural infection (20), our finding that intranasal vaccination–induced spike-specific sIgA descended to 35% of its peak level after 3 months suggests that an intranasal booster may be needed every 6–9 months to maintain effective protection against infection. We tried stratifying the nasal sIgA and serum antibodies between uninfected and infected participants (Supplemental Figure 2). On day 14 after the first dose, the mean GMFI of nasal sIgA for BA.1+L452R (BA.5-like) was 8.0 versus 4.5 between infected and uninfected on days 15–28, whereas the mean GMFI of serum neutralization for BA.5 was 8.3 versus 4.2. Both nasal sIgA and serum neutralization showed a trend of greater induction (nearly 2-fold) among uninfected participants but lack of statistical significance, probably due to relatively small sample size and short observation duration (14–28 days after the first dose) because the second dose was initiated on day 28. On day 14 after the second dose, the mean GMFI of nasal sIgA for BA.1+L452R (BA.5-like) had an 11.5-fold increase from 1:5.6 to 1:64.5. In contrast, serum neutralizing GMFI for BA.5 had only a 3.1-fold increase from 1:5.5 to 1:16.8. Serum neutralizing titer for BA.5 had only a 3.4-fold increase from 1:89 to 1:303, which was lower than intramuscularly injected vaccines that can elicit much higher serum neutralizing titer but still had Omicron breakthrough infections. Intramuscularly injected vaccines can elicit much higher serum neutralizing titer but are limited in preventing Omicron breakthrough infections. Given that accumulated evidence showed that the level of nasal spike-specific sIgA is inversely correlated with the risk of SARS-CoV-2 Omicron infection, we believe that the dramatic induction of nasal spike-specific sIgA after intranasal booster is the key contributor to the defense against infection through the airway. In conclusion, this study demonstrated that a 2-dose intranasal vaccination regimen using NB2155 can induce spike-specific sIgA in the nasal mucosa and potentially contribute to protection against Omicron infection. Further clinical studies should be conducted to develop a safe, effective, and user-friendly vaccine for preventing infections and blocking virus transmission in the population.
No comment yet.
Scooped by Gilbert C FAURE
September 13, 3:54 AM
Scoop.it!

Optimizing the safety of antibody–drug conjugates for patients with solid tumours | Nature Reviews Clinical Oncology

Optimizing the safety of antibody–drug conjugates for patients with solid tumours | Nature Reviews Clinical Oncology | Immunology and Biotherapies | Scoop.it
Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs) have enabled major advances that have reshaped the treatment of several advanced-stage solid tumours. Considering the intended rationale behind the design of ADCs, which is to achieve targeted delivery of cytotoxic molecules by linking them to antibodies targeting tumour-specific antigens, ADCs would be expected to be less toxic than conventional chemotherapy. However, most ADCs are still burdened by off-target toxicities that resemble those of the cytotoxic payload as well as on-target toxicities and other poorly understood and potentially life-threatening adverse effects. Given the rapid expansion in the clinical indications of ADCs, including use in curative settings and various combinations, extensive efforts are ongoing to improve their safety. Approaches currently being pursued include clinical trials optimizing the dose and treatment schedule, modifications of each ADC component, identification of predictive biomarkers for toxicities, and the development of innovative diagnostic tools. In this Review, we describe the determinants of the toxicities of ADCs in patients with solid tumours, highlighting key strategies that are expected to improve tolerability and enable improvements in the treatment outcomes of patients with advanced-stage and those with early stage cancers in the years to come. Advances in technology have enabled the development of several novel antibody–drug conjugates (ADCs) with encouraging clinical activity in patients with advanced-stage solid tumours. Indications for these therapies are expanding rapidly to earlier lines of therapy. Nonetheless, the toxicities of these various agents are not trivial and can be fatal, even in patients with early stage disease. In this Review, the authors summarize the toxicities of ADCs in patients with solid tumours both as monotherapies and in combination with other agents and discuss various ongoing research efforts attempting to optimize the therapeutic index of these agents.
No comment yet.
Scooped by Gilbert C FAURE
September 2, 7:37 AM
Scoop.it!

Fentanyl vaccine heads for clinical trials, with goal of saving lives

Fentanyl vaccine heads for clinical trials, with goal of saving lives | Immunology and Biotherapies | Scoop.it
A fentanyl vaccine developed by researchers at the University of Houston is expected to head to clinical trials sometime in the middle of next year, with the hope of being a groundbreaking solution to a deadly crisis.
No comment yet.
Scooped by Gilbert C FAURE
August 13, 4:39 AM
Scoop.it!

Alexis Capelle on LinkedIn: 💉 mRNA Technologies Beyond COVID-19: What’s Next & Who Are the Leading…

Alexis Capelle on LinkedIn: 💉 mRNA Technologies Beyond COVID-19: What’s Next & Who Are the Leading… | Immunology and Biotherapies | Scoop.it
💉 mRNA Technologies Beyond COVID-19: What’s Next & Who Are the Leading Companies Revolutionizing This Space?

mRNA-based vaccines have shown rapid and precise…
No comment yet.
Scooped by Gilbert C FAURE
July 31, 9:45 AM
Scoop.it!

Professor Erwin Loh on LinkedIn: #llama #nanobodies #hiv #immunity #advancedscience

Professor Erwin Loh on LinkedIn: #llama #nanobodies #hiv #immunity #advancedscience | Immunology and Biotherapies | Scoop.it
#Llama 🦙 #nanobodies: A breakthrough in building #HIV #immunity - Researchers immunized llamas with a specially designed HIV-1 envelope protein to produce…
No comment yet.
Scooped by Gilbert C FAURE
July 22, 2:03 PM
Scoop.it!

Inhibition of IL-11 signalling extends mammalian healthspan and lifespan

Inhibition of IL-11 signalling extends mammalian healthspan and lifespan | Immunology and Biotherapies | Scoop.it
For healthspan and lifespan, ERK, AMPK and mTORC1 represent critical pathways and inflammation is a centrally important hallmark1–7. Here we examined whether IL-11, a pro-inflammatory cytokine of the IL-6 family, has a negative effect on age-associated disease and lifespan. As mice age, IL-11 is upregulated across cell types and tissues to regulate an ERK–AMPK–mTORC1 axis to modulate cellular, tissue- and organismal-level ageing pathologies. Deletion of Il11 or Il11ra1 protects against metabolic decline, multi-morbidity and frailty in old age. Administration of anti-IL-11 to 75-week-old mice for 25 weeks improves metabolism and muscle function, and reduces ageing biomarkers and frailty across sexes. In lifespan studies, genetic deletion of Il11 extended the lives of mice of both sexes, by 24.9% on average. Treatment with anti-IL-11 from 75 weeks of age until death extends the median lifespan of male mice by 22.5% and of female mice by 25%. Together, these results demonstrate a role for the pro-inflammatory factor IL-11 in mammalian healthspan and lifespan. We suggest that anti-IL-11 therapy, which is currently in early-stage clinical trials for fibrotic lung disease, may provide a translational opportunity to determine the effects of IL-11 inhibition on ageing pathologies in older people. IL-11 is identified as a key regulator of ERK–AMPK–mTORC1 signalling, metabolism, inflammation and age-related disease and lifespan in mouse and human.
No comment yet.
Scooped by Gilbert C FAURE
July 20, 8:29 AM
Scoop.it!

Mice live longer when inflammation-boosting protein is blocked

Mice live longer when inflammation-boosting protein is blocked | Immunology and Biotherapies | Scoop.it
Humans also have the protein, called IL-11, offering hope for a future longevity treatment.
No comment yet.
Scooped by Gilbert C FAURE
July 16, 1:21 PM
Scoop.it!

Efficacy and Safety of Nipocalimab in Sjögren’s Disease: Phase 2 Trial Results - Physician's Weekly

Efficacy and Safety of Nipocalimab in Sjögren’s Disease: Phase 2 Trial Results - Physician's Weekly | Immunology and Biotherapies | Scoop.it
Nipocalimab showed a significant decrease in Clinical European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index.
No comment yet.
Scooped by Gilbert C FAURE
July 7, 8:44 AM
Scoop.it!

https://www.niaid.nih.gov/news-events/nih-sponsored-trial-nasal-covid-19-vaccine-opens?utm_medium=social&utm_source=linkedin&utm_campaign=news_covid19_trial_7012024

No comment yet.
Scooped by Gilbert C FAURE
May 27, 11:42 AM
Scoop.it!

Chine : un foie de porc transplanté sur un patient vivant

Chine : un foie de porc transplanté sur un patient vivant | Immunology and Biotherapies | Scoop.it
Le 24 mai, des chercheurs chinois ont annoncé avoir transplanté avec succès un foie de porc génétiquement modifié sur un patient humain vivant atteint d’un cancer du foie.
No comment yet.